Bavarian Nordic (public company)

Bavarian Nordic is a biotechnology company specializing in research, development and manufacture of active cancer immunotherapies and vaccines for infectious diseases.

Developing cancer immunotherapies and vaccines for infectious diseases, Bavarian Nordic has a market cap of €1Bn (7.5Bn DKK) on the Nasdaq Copenhagen, and has over 400 employees worldwide.

Its PROSTVAC vaccine for cancer, based in a virus, has been under fire, but Bavarian Nordic’s pipeline in infectious disease seems solid, and includes a new programme for Ebola.